Cargando…

Systematic Review and Meta-analysis of the Survival Outcomes of First-line Treatment Options in High-risk Prostate Cancer

Prostate cancer (PCa) is the most common non-dermatologic cancer in the western countries in western countries. High-risk PCa accounts for 15% of the diagnosed cases. In this study, we compare the long-term survival outcomes of radical prostatectomy (RP), radiation therapy (RT), brachytherapy (BT),...

Descripción completa

Detalles Bibliográficos
Autores principales: Lei, Jun H., Liu, Liang R., Wei, Qiang, Yan, Shi B., Song, Tu R., Lin, Fu S., Yang, Lu, Cao, De H., Yuan, Hai C., Xue, Wen B., Lv, Xiao, Cai, Ying C., Zeng, Hao, Han, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378991/
https://www.ncbi.nlm.nih.gov/pubmed/25578739
http://dx.doi.org/10.1038/srep07713
_version_ 1782519521601388544
author Lei, Jun H.
Liu, Liang R.
Wei, Qiang
Yan, Shi B.
Song, Tu R.
Lin, Fu S.
Yang, Lu
Cao, De H.
Yuan, Hai C.
Xue, Wen B.
Lv, Xiao
Cai, Ying C.
Zeng, Hao
Han, Ping
author_facet Lei, Jun H.
Liu, Liang R.
Wei, Qiang
Yan, Shi B.
Song, Tu R.
Lin, Fu S.
Yang, Lu
Cao, De H.
Yuan, Hai C.
Xue, Wen B.
Lv, Xiao
Cai, Ying C.
Zeng, Hao
Han, Ping
author_sort Lei, Jun H.
collection PubMed
description Prostate cancer (PCa) is the most common non-dermatologic cancer in the western countries in western countries. High-risk PCa accounts for 15% of the diagnosed cases. In this study, we compare the long-term survival outcomes of radical prostatectomy (RP), radiation therapy (RT), brachytherapy (BT), androgen- deprivation therapy (ADT), and watchful waiting (WW) in high-risk prostate cancer (PCa). Overall, RP/(RT plus ADT) gave the best survival outcome in patients with high-risk PCa, whereas ADT/WW had the worst outcome. The overall priority for treatment strategy could be ranked as follows: RP/(RT plus ADT), RT, and ADT/WW. RP had significant better overall survival (OS) than RT or BT, and RP had significant lower cancer-specific mortality (CSM) than RT (0.51 [95% CI 0.30–0.73], P<0.001). ADT improved the cancer-specific survival (CSS) of RP based on a case-controlled study; added ADT to RT failed to challenge the position of RP but could improve the outcome of RT. In conclusions,RP/(RT plus adjuvant ADT) could both be used for the first-line therapy of high-risk PCa. When encountering an individual patient, urologists should consider various factors like tumors themselves, preferences of individuals, and so on.
format Online
Article
Text
id pubmed-5378991
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-53789912017-04-07 Systematic Review and Meta-analysis of the Survival Outcomes of First-line Treatment Options in High-risk Prostate Cancer Lei, Jun H. Liu, Liang R. Wei, Qiang Yan, Shi B. Song, Tu R. Lin, Fu S. Yang, Lu Cao, De H. Yuan, Hai C. Xue, Wen B. Lv, Xiao Cai, Ying C. Zeng, Hao Han, Ping Sci Rep Article Prostate cancer (PCa) is the most common non-dermatologic cancer in the western countries in western countries. High-risk PCa accounts for 15% of the diagnosed cases. In this study, we compare the long-term survival outcomes of radical prostatectomy (RP), radiation therapy (RT), brachytherapy (BT), androgen- deprivation therapy (ADT), and watchful waiting (WW) in high-risk prostate cancer (PCa). Overall, RP/(RT plus ADT) gave the best survival outcome in patients with high-risk PCa, whereas ADT/WW had the worst outcome. The overall priority for treatment strategy could be ranked as follows: RP/(RT plus ADT), RT, and ADT/WW. RP had significant better overall survival (OS) than RT or BT, and RP had significant lower cancer-specific mortality (CSM) than RT (0.51 [95% CI 0.30–0.73], P<0.001). ADT improved the cancer-specific survival (CSS) of RP based on a case-controlled study; added ADT to RT failed to challenge the position of RP but could improve the outcome of RT. In conclusions,RP/(RT plus adjuvant ADT) could both be used for the first-line therapy of high-risk PCa. When encountering an individual patient, urologists should consider various factors like tumors themselves, preferences of individuals, and so on. Nature Publishing Group 2015-01-12 /pmc/articles/PMC5378991/ /pubmed/25578739 http://dx.doi.org/10.1038/srep07713 Text en Copyright © 2015, Macmillan Publishers Limited. All rights reserved http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Lei, Jun H.
Liu, Liang R.
Wei, Qiang
Yan, Shi B.
Song, Tu R.
Lin, Fu S.
Yang, Lu
Cao, De H.
Yuan, Hai C.
Xue, Wen B.
Lv, Xiao
Cai, Ying C.
Zeng, Hao
Han, Ping
Systematic Review and Meta-analysis of the Survival Outcomes of First-line Treatment Options in High-risk Prostate Cancer
title Systematic Review and Meta-analysis of the Survival Outcomes of First-line Treatment Options in High-risk Prostate Cancer
title_full Systematic Review and Meta-analysis of the Survival Outcomes of First-line Treatment Options in High-risk Prostate Cancer
title_fullStr Systematic Review and Meta-analysis of the Survival Outcomes of First-line Treatment Options in High-risk Prostate Cancer
title_full_unstemmed Systematic Review and Meta-analysis of the Survival Outcomes of First-line Treatment Options in High-risk Prostate Cancer
title_short Systematic Review and Meta-analysis of the Survival Outcomes of First-line Treatment Options in High-risk Prostate Cancer
title_sort systematic review and meta-analysis of the survival outcomes of first-line treatment options in high-risk prostate cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378991/
https://www.ncbi.nlm.nih.gov/pubmed/25578739
http://dx.doi.org/10.1038/srep07713
work_keys_str_mv AT leijunh systematicreviewandmetaanalysisofthesurvivaloutcomesoffirstlinetreatmentoptionsinhighriskprostatecancer
AT liuliangr systematicreviewandmetaanalysisofthesurvivaloutcomesoffirstlinetreatmentoptionsinhighriskprostatecancer
AT weiqiang systematicreviewandmetaanalysisofthesurvivaloutcomesoffirstlinetreatmentoptionsinhighriskprostatecancer
AT yanshib systematicreviewandmetaanalysisofthesurvivaloutcomesoffirstlinetreatmentoptionsinhighriskprostatecancer
AT songtur systematicreviewandmetaanalysisofthesurvivaloutcomesoffirstlinetreatmentoptionsinhighriskprostatecancer
AT linfus systematicreviewandmetaanalysisofthesurvivaloutcomesoffirstlinetreatmentoptionsinhighriskprostatecancer
AT yanglu systematicreviewandmetaanalysisofthesurvivaloutcomesoffirstlinetreatmentoptionsinhighriskprostatecancer
AT caodeh systematicreviewandmetaanalysisofthesurvivaloutcomesoffirstlinetreatmentoptionsinhighriskprostatecancer
AT yuanhaic systematicreviewandmetaanalysisofthesurvivaloutcomesoffirstlinetreatmentoptionsinhighriskprostatecancer
AT xuewenb systematicreviewandmetaanalysisofthesurvivaloutcomesoffirstlinetreatmentoptionsinhighriskprostatecancer
AT lvxiao systematicreviewandmetaanalysisofthesurvivaloutcomesoffirstlinetreatmentoptionsinhighriskprostatecancer
AT caiyingc systematicreviewandmetaanalysisofthesurvivaloutcomesoffirstlinetreatmentoptionsinhighriskprostatecancer
AT zenghao systematicreviewandmetaanalysisofthesurvivaloutcomesoffirstlinetreatmentoptionsinhighriskprostatecancer
AT hanping systematicreviewandmetaanalysisofthesurvivaloutcomesoffirstlinetreatmentoptionsinhighriskprostatecancer